A 24-wk Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of a New PDE4 Inhibitor in Patients With COPD
Status:
Completed
Trial end date:
2018-01-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the dose-response relationship of different doses of
CHF6001 and to identify the optimal dose (s) in terms of benefit/risk ratio for further
development in the target patient population.